Q3 FY2026 · ended Sep 30, 2026 · Revenue $1.50M, +1209.2% YoY · Filed Nov 5, 2026
Lipocine Inc. (LPCN) files with the SEC under industry code 2834, Pharmaceutical Preparations. In Q3 of fiscal 2026, the quarter ended Sep 30, 2026, it reported revenue of $1.5 million and a net loss of $666,192.
Revenue
$1.50M
+1209.2% vs year-ago quarter
Net income
$-666,192
+79.1% vs year-ago quarter
Operating cash flow
$-1.81M
+39.5% vs year-ago quarter
Free cash flow
$1.69M
EPS
$-0.08
+86.4% vs year-ago quarter
Dividend per share
None
Shares outstanding
11.07M
+99.5% vs year-ago quarter
Net cash
—
Operating margin
-338.5%
TTM
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- LPCN (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Salt Lake City, United States
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1535955
- Former names
- MARATHON BAR CORP (until Jul 9, 2013)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q3 FY2026 Sep 30, 2026 |
Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
|---|---|---|---|---|---|
| Revenue | $1.5M | $190,099 | $119,397 | $1.1M | $114,574 |
| Operating income | -$868,525 | -$2.8M | -$3.8M | -$2.5M | -$3.4M |
| Net income | -$666,192 | -$2.6M | -$3.7M | -$2.4M | -$3.2M |
| Diluted EPS | -$0.08 | -$0.32 | -$0.54 | -$0.35 | -$0.59 |
| Operating cash flow | -$1.8M | -$3.0M | -$2.3M | -$2.9M | -$3.0M |
| Total assets | $23.2M | $23.8M | $25.4M | $17.0M | $16.1M |
| Total liabilities | $2.0M | $2.1M | $2.5M | $2.5M | $1.9M |
| Stockholders' equity | $21.2M | $21.8M | $22.8M | $14.5M | $14.1M |
| Cash and investments | $21.5M | $23.3M | $24.7M | $14.9M | $15.1M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Results of operations
|
Nov 5, 2026 | Nov 5, 2026 |
| 10-Q | Quarterly report | Nov 5, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Other events
|
Oct 20, 2026 | Oct 20, 2026 |
| 8-K |
Current report
Other events
|
Oct 7, 2026 | Oct 7, 2026 |
| 8-K |
Current report
Other events
|
Sep 16, 2026 | Sep 16, 2026 |
| 8-K |
Current report
Other events
|
Sep 14, 2026 | Sep 14, 2026 |
All 823 Lipocine Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.